Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 274, Issue 1-2, Pages 39-41Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2008.03.022
Keywords
Antigen presentation; Brain; Crohn's disease; Immunosuppression; Inflammatory bowel disease; Integrin; JC virus; Natalizumab; Perivascular spaces; Pharmacotherapy; PML; Polyoma virus; Progressive multifocal leukoencephalopathy; Tysabri; Virchow Robin space
Categories
Ask authors/readers for more resources
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS). Natalizumab ((R) Tysabri) is a humanized recombinant monoclonal antibody that binds to the alpha (alpha)(4) chain of the alpha(4) beta (beta)(1) integrin (very late activation antigen 4; VLA-4), and alpha(4)beta(7) integrin. Recently, two patients with MS and one patient with Crohn's disease who were treated with natalizumab in the setting of clinical trials developed progressive multifocal leukoencephalopathy (PML), an opportunistic infection of the brain with the polyoma virus JC. We recently showed that natalizumab decreases the numbers of CD4(+) and CD8(+) T lymphocytes, CD19(+) B cells, and CD138(+) plasma cells in the cerebrospinal fluid (CSF) of patients with MS on natalizumab therapy. In addition, we demonstrated that the cell numbers in CSF remained unchanged even 6 months after cessation of natalizumab treatment. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available